Acalabrutinib-d3

Acalabrutinib-d3 is a deuterium-labeled derivative of Acalabrutinib, which is a Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of certain types of cancers, such as mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Specifically, Acalabrutinib-d3 is used as an internal standard for the quantification of Acalabrutinib in biological samples using mass spectrometry. Chemically, Acalabrutinib-d3 has the same molecular formula as Acalabrutinib (C26H23N7O2S), except that three hydrogen atoms in the molecule have been replaced with deuterium atoms. This labeling results in a mass shift of three atomic mass units, allowing for accurate and precise quantification of Acalabrutinib in biological matrices. In terms of usage, Acalabrutinib-d3 is typically used in pharmacokinetic studies to determine the drug’s absorption, distribution, metabolism, and excretion (ADME) properties in humans and animals. It is also used in drug-drug interaction studies to assess the potential for Acalabrutinib to interact with other drugs and affect their ADME properties. Overall, Acalabrutinib-d3 is a valuable tool for researchers and clinicians in the development and optimization of Acalabrutinib-based therapies for the treatment of cancer. Its chemical properties and usage in pharmacokinetic studies ensure the safe and effective use of Acalabrutinib in clinical practice.